How many drugs treat Itching of skin?

Drug Landscape tracks 10 marketed treatments for Itching of skin (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/itching-of-skin.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Itching of skin — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Itching of skin (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Itching of skin, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Ulesfia	BENZYL ALCOHOL	Shionogi	Pediculicide [EPC]		2009-01-01
Tetracaine Hydrochloride	TETRACAINE	Alcon Labs	Ester Local Anesthetic	Sodium channel protein type 7 subunit alpha	2005-01-01
Emadine	EMEDASTINE	Novartis	Histamine-1 Receptor Inhibitor	Histamine H1 receptor	1997-01-01
Phenazoline	ANTAZOLINE	Novartis	antazoline	Histamine H1 receptor	1990-01-01
Lac-Hydrin	AMMONIUM LACTATE	Sun Pharma	alpha-Hydroxy Acid [EPC]		1985-01-01
Actidil	TRIPROLIDINE	Novartis	triprolidine	Histamine H1 receptor	1983-01-01
Hispril	DIPHENYLPYRALINE	GSK	diphenylpyraline	Histamine H1 receptor	1982-01-01
Galzin	ZINC ACETATE	Eton	zinc acetate		1980-01-01
Karbinal Er	CARBINOXAMINE	Mcneil	Histamine-1 Receptor Antagonist	Histamine H1 receptor	1974-01-01
Pyrilamine	mepyramine	Impax Labs	Central Nervous System Stimulant [EPC]	Histamine H1 receptor	1973-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 22 drugs in Itching of skin
Novartis · 4 drugs in Itching of skin
Bayer · 3 drugs in Itching of skin
Pfizer · 2 drugs in Itching of skin
Fresenius Kabi · 1 drug in Itching of skin
GSK · 1 drug in Itching of skin
Impax Labs · 1 drug in Itching of skin
Innocoll · 1 drug in Itching of skin
Journey · 1 drug in Itching of skin
King Faisal Specialist Hospital & Research Center · 1 drug in Itching of skin
Mcneil · 1 drug in Itching of skin
Merck & Co. · 1 drug in Itching of skin

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Itching of skin:

Cite this brief

Drug Landscape (2026). Itching of skin — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/itching-of-skin. Accessed 2026-06-10.

Itching of skin full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing